TrialHaematologica2024

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.

Luděk Pour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.